Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling

Plasma concentrations of dabigatran, an active principle of prodrug dabigatran etexilate (DABE), are increased by renal impairment (RI) or coadministration of a P‐glycoprotein inhibitor. Because the combined effects of drug–drug interactions and RI have not been evaluated by means of clinical studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Doki, Kosuke, Neuhoff, Sibylle, Rostami‐Hodjegan, Amin, Homma, Masato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389344/
https://www.ncbi.nlm.nih.gov/pubmed/30659778
http://dx.doi.org/10.1002/psp4.12382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389344/
https://www.ncbi.nlm.nih.gov/pubmed/30659778
http://dx.doi.org/10.1002/psp4.12382

Ejemplares similares